Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Cartesian Therapeutics Inc (NASDAQ: RNAC) closed at $9.16 up 0.16% from its previous closing price of $9.15. In other words, the price has increased by $0.16 from its previous closing price. On the day, 53651.0 shares were traded. RNAC stock price reached its highest trading level at $9.355 during the session, while it also had its lowest trading level at $9.0.
Ratios:
For a deeper understanding of Cartesian Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.70 and its Current Ratio is at 12.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 19, 2024, initiated with a Buy rating and assigned the stock a target price of $42.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 10 ’25 when SPRINGER TIMOTHY A bought 48,595 shares for $10.47 per share. The transaction valued at 508,751 led to the insider holds 620,175 shares of the business.
SPRINGER TIMOTHY A bought 41,782 shares of RNAC for $393,947 on Apr 09 ’25. The Director now owns 571,580 shares after completing the transaction at $9.43 per share. On Apr 11 ’25, another insider, SPRINGER TIMOTHY A, who serves as the Director of the company, bought 36,338 shares for $10.77 each. As a result, the insider paid 391,455 and bolstered with 656,513 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNAC now has a Market Capitalization of 237741392 and an Enterprise Value of 71373304. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.96. Its current Enterprise Value per Revenue stands at 2.089 whereas that against EBITDA is -1.69.
Stock Price History:
The Beta on a monthly basis for RNAC is 0.34, which has changed by -0.67586696 over the last 52 weeks, in comparison to a change of 0.09362543 over the same period for the S&P500. Over the past 52 weeks, RNAC has reached a high of $41.87, while it has fallen to a 52-week low of $8.85. The 50-Day Moving Average of the stock is -23.42%, while the 200-Day Moving Average is calculated to be -45.22%.
Shares Statistics:
For the past three months, RNAC has traded an average of 99.46K shares per day and 62290 over the past ten days. A total of 25.94M shares are outstanding, with a floating share count of 8.31M. Insiders hold about 67.98% of the company’s shares, while institutions hold 20.21% stake in the company. Shares short for RNAC as of 1745971200 were 2534226 with a Short Ratio of 25.48, compared to 1743379200 on 2097191. Therefore, it implies a Short% of Shares Outstanding of 2534226 and a Short% of Float of 24.64.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
